English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
Novotech 收购美国药物开发咨询公司 CBR International
Jan 12, 2023 15:00 HKT
Novotech 收購美國藥物開發諮詢公司 CBR International
Jan 12, 2023 15:00 HKT
Novotech 收购欧洲 CRO——加强全球运营
Jan 12, 2023 15:00 HKT
Novotech 收購歐洲 CRO——加強全球運營
Jan 12, 2023 15:00 HKT
노보텍, 미국 기반의 의약품 개발 컨설팅 회사인 CBR 인터내셔널 인수
Jan 12, 2023 15:00 HKT
노보텍, 유럽 CRO 인수 - 글로벌 운영 강화
Jan 12, 2023 15:00 HKT
Avance Clinical 庆祝GlobalReady成功 超过40家生物技术客户进入计划
Jan 12, 2023 07:00 HKT
Avance Clinical 慶祝GlobalReady成功 超過40家生物技術客戶進入計劃
Jan 12, 2023 07:00 HKT
아방스 클리니컬, GlobalReady 성공 축하 40개 이상의 생명공학 고객이 프로그램에 참여
Jan 12, 2023 07:00 HKT
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
Jan 11, 2023 21:00 HKT
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
Jan 11, 2023 15:00 HKT
Prenetics旗下的行动基因的ACTOnco® IVD产品获得FDA许可 成为首家就适用于所有实体肿瘤的癌症基因检测取得许可的亚洲公司
Jan 11, 2023 11:21 HKT
Prenetics旗下的行動基因的ACTOnco® IVD產品獲得FDA許可 成為首家就適用於所有實體腫瘤的癌症基因檢測取得許可的亞洲公司
Jan 11, 2023 11:20 HKT
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Jan 11, 2023 11:19 HKT
君聖泰HTD1801治療非酒精性脂肪性肝炎(NASH)的臨床IIb 期研究(CENTRICITY研究)完成首例患者給藥
Jan 11, 2023 08:01 HKT
君圣泰HTD1801治疗非酒精性脂肪性肝炎(NASH)的临床IIb 期研究(CENTRICITY研究)完成首例患者给药
Jan 11, 2023 08:00 HKT
医思健康向赴港旅客提供复必泰二价疫苗服务
Jan 10, 2023 18:03 HKT
醫思健康向赴港旅客提供復必泰二價疫苗服務
Jan 10, 2023 18:02 HKT
China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate
Jan 10, 2023 16:33 HKT
Malaysian Genomics Explores R&D Collaboration with SIRIM
Jan 09, 2023 14:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: